Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Feb 28, 2025 · 10-K · 59 days after period end · 0000950170-25-029973
| Metric | Q4 2024 | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $658.41M | $463.53M | $235.93M | $178.73M |
| Net Income | $159.05M | $45.66M | -$109.24M | -$121.98M |
| EPS Diluted | $1.50 | — |
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
| — |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 28, 2025 · 59 d after period end
